$37.78 Million in Sales Expected for Sarepta Therapeutics, Inc. (SRPT) This Quarter
Wall Street analysts forecast that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will post sales of $37.78 million for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $36.50 million and the highest estimate coming in at $39.38 million. The firm is scheduled to report its next earnings report on Thursday, October 26th.
On average, analysts expect that Sarepta Therapeutics will report full-year sales of $37.78 million for the current year, with estimates ranging from $129.70 million to $145.80 million. For the next financial year, analysts anticipate that the firm will post sales of $260.71 million per share, with estimates ranging from $196.51 million to $334.10 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. The business’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same period last year, the company earned ($1.19) earnings per share.
A number of research analysts have recently weighed in on the company. Janney Montgomery Scott raised their price target on Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. Morgan Stanley restated an “equal weight” rating and issued a $33.00 price target (up previously from $31.00) on shares of Sarepta Therapeutics in a research report on Thursday, July 20th. Robert W. Baird restated an “outperform” rating and issued a $96.00 price target (down previously from $102.00) on shares of Sarepta Therapeutics in a research report on Friday, July 21st. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, July 27th. Finally, Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Eight research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $61.28.
In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $410,000.00. Following the completion of the sale, the director now owns 62,471 shares in the company, valued at approximately $2,561,311. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares of the company’s stock, valued at approximately $1,173,596.64. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock valued at $3,224,208 in the last 90 days. 9.60% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Asymmetry Capital Management L.P. boosted its stake in Sarepta Therapeutics by 82.2% in the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock valued at $5,353,000 after buying an additional 71,630 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 271 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in Sarepta Therapeutics by 85.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock valued at $704,000 after buying an additional 9,635 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Sarepta Therapeutics by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 1,435 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $3,806,000. Institutional investors own 63.11% of the company’s stock.
WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/27/37-78-million-in-sales-expected-for-sarepta-therapeutics-inc-srpt-this-quarter.html.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 36.51 on Friday. The stock’s market capitalization is $2.35 billion. The stock has a 50 day moving average of $37.65 and a 200-day moving average of $33.32. Sarepta Therapeutics has a 52 week low of $25.47 and a 52 week high of $63.73.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.